EON: Enhanced Online News (press release) At the recommended dose of one 125 mg delayed-release tablet taken orally, twice daily, Fulyzaq™ works to inhibit both the cyclic adenosine monophosphate (cAMP)-stimulated cystic fibrosis transmembrane conductance regulator (CFTR) chloride ion (C1-) ...
PharmaTimes Dr Soriot concluded by saying that "combined with our on-market portfolio, including Symbicort ( budesonide /formoterol), and our strong pipeline, the agreement will enable us to offer further distinctive treatment options across the full spectrum of ...
Daily Political Most notably, physicians are very satisfied with Uceris, ascribing high marks on efficacy/tolerability. Prescribing comfort is driven by familiarity with budesonide (from Entecort) and MMX delivery (from Lialda). Interestingly, over half surveyed ... and more »
Genetic Engineering News Once completed, AstraZeneca would expand its respiratory disease portfolio beyond its Symbicort, a maintenance treatment for asthma in patients ...
Ticker Report Most notably, physicians are very satisfied with Uceris, ascribing high marks on efficacy/tolerability. Prescribing comfort is driven by familiarity with budesonide (from Entecort) and MMX delivery (from Lialda). Interestingly, over half surveyed ...
Benzinga Most notably, physicians are very satisfied with Uceris, ascribing high marks on efficacy/tolerability. Prescribing comfort is driven by familiarity with budesonide (from Entecort) and MMX delivery (from Lialda). Interestingly, over half surveyed ... and more »
Xconomy The field for COPD treatments is very crowded, and AstraZeneca knows it well: it's made billions off of drugs such as budesonide (Pulmicort), an inhalable gluc...
Seeking Alpha The company's current commercial efforts are focused on five products: UCERIS™ (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® ( omeprazole /sodium ...
